Yael L. Maxwell
@TCTMD_Yael
Followers
4K
Following
5K
Media
808
Statuses
6K
Senior Medical Journalist @TCTMD & #FellowsForum Section Editor. Mama to 2 tiny humans. Student of the world. All tweets my own. @yaelmaxwell.bsky.social
Joined October 2011
I set up a Signal account if anyone would prefer to reach me there.
0
1
2
My first story from #EACTS2025 dives into a unique analysis comparing 5-year TAVI vs SAVR mortality that provoked some strong feelings about what type of research should inform guidelines. @MMarinCuartas @eduardosaadi
https://t.co/2EFOjzSNN4
tctmd.com
The findings sparked a debate about the merits of RCTs vs other study designs—one surgeon urged others to “read a textbook.”
0
2
4
A new scientific statement from @American_Heart encourages cardiologists and other healthcare practitioners to emphasize the importance of psychological health and well-being for patients during post-MI recovery. More here: https://t.co/2FyNlbUZvq
0
1
1
But also, can we talk about the cloud of cigarette smoke you have to walk through to enter and leave the convention center? At a heart surgery conference? #EACTS2025
0
1
10
Mechanisms to improve cancer cachexia via GDF-15 inhibition did not improve outcomes in HF (if not, worse). While not required for clinical dev, human genetic analyses have not been consistent with the trial's therapeutic hypothesis (e.g., https://t.co/buKvhwBIAP
@CircAHA)
ahajournals.org
Background: Heart failure (HF) is a highly prevalent disorder for which disease mechanisms are incompletely understood. The discovery of disease-associated proteins with causal genetic evidence...
1
7
28
“The time-sensitive nature of transthyretin cardiomyopathy is something that has been on many people’s minds, but I think this is the first piece of evidence that should push us forward,” said @MasriAhmadMD at #HFSA2025. Discussion from @HannaGaggin.
0
5
13
In the phase III CELEBRATE trial, the novel injectable glycoprotein IIb/IIIa inhibitor zalunfiban has met its primary safety and efficacy outcomes in STEMI patients. Read more here: https://t.co/G4ryRQHib7
0
1
2
“You often learn from when science goes the opposite direction from what you expect,” said presenter @ddbergMD. The next question to answer is what role GDF-15 plays in heart failure. #HFSA2025
0
1
0
Another from #HFSA2025: this time looking at a new CCM-D device in patients with HFrEF. Will this be enough for CCM to gain traction in the HF world? @NirUrielMD @BurkhoffMd @SantosGallegoMD
https://t.co/xtt4p9cxVJ
tctmd.com
The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms.
0
2
7
My first from #HFSA2025 and an interesting one to boot! The Cordio HearO App can pick up signals of heart failure events more than 3 weeks before they happen. Thanks for your time @TheHeartBeat3 and to @BurkhoffMd for comment.
Voice Analysis Picks Up Patients at Risk for HF Hospitalization: COMMUNITY-HF https://t.co/u8swXQz0pv
0
1
1
Fantastic write up by @TCTMD_Yael on our lab’s work trying to democratize AI for @ASE360 echocardiography! Lead by @Yuki_Sahashi, EchoNet-Measurements has the most training data of AI echo annotation models and is open source. A good benchmark for when your #echofirst labs
2
5
21
Earlier, less invasive treatment is the name of the game according to new @ESCardioNews and @EACTS valvular heart disease guidelines. #ESCongress @FabienPraz @Eric_Van_Belle
https://t.co/XckNXwON6r
tctmd.com
Among the changes are a lower TAVI age cutoff and greater emphasis on patient education and coronary CTA.
0
0
1
The TCTMD editorial team @TCTMD_Caitlin, @ToddNeale, @lamckeown1, @TCTMD_Yael, and @michaelTCTMD share their top news stories for August, and special guest @mmamas1973 highlights his top picks for ESC 2025 in Madrid. Listen to Heart Sounds here: https://t.co/WkZ6P6RBPi
0
6
18
New US hypertension guidelines, the first since 2017, released today reinforce prior recs that prioritize lowering BP early and aggressively, with special emphasis on lifestyle, the connection between BP and cognitive function, and pregnancy. https://t.co/fouFdzokK8
tctmd.com
The document, last updated in 2017, promotes use of the PREVENT calculator as well as more flexible BP goals.
0
9
9
During #NYValves2025, Patrick O'Gara, Michael Borger, and @TCTMD_Yael discussed how the FDA approval of asymptomatic TAVI has changed practice, with perspectives from the US and Europe. Watch the full episode of On Record here: https://t.co/o9ubhg4qeS
1
1
3
CT-guided PCI is no longer just a pipe dream but rather a strategy already practiced and likely to arrive at more cath labs soon, said experts in a @SCAI/@Heart_SCCT session at #SCCT2025
https://t.co/5MS3ckUeVL
@yadersandoval @JonathonLeipsic @ESHLOF @FaroucJaffer
tctmd.com
A joint SCCT/SCAI panel reviewed many opportunities for CT to enhance procedural planning and foster multidisciplinary care.
1
15
34
In this episode of Heart Sounds, our TCTMD journalists discuss the top news in cardiology for July. @TCTMD_Yael @TCTMD_Caitlin @lamckeown1 @ToddNeale
https://t.co/L834ZXB0r7
1
3
4
Whether a patient undergoes CAC screening depends on the type of doctor they see, with large sex differences observed over the past decade at a single healthcare system, according to retrospective data. #SCCT2025 @TOyourMD @MBittencourtMD
https://t.co/V66WcnHpuv
tctmd.com
The decade-long, single-healthcare-system study gives insights into how physicians are using CAC tests and in which patients.
0
3
5